Practical insights into chronic management of hepatic Wilson's disease

被引:3
作者
Lynch, Erica Nicola [1 ]
Campani, Claudia [1 ,2 ]
Innocenti, Tommaso [1 ]
Dragoni, Gabriele [1 ,3 ]
Forte, Paolo [4 ]
Galli, Andrea [1 ,5 ]
机构
[1] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Gastroenterol Res Unit, I-50134 Florence, Italy
[2] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy
[3] Univ Siena, Dept Med Biotechnol, I-53100 Siena, Italy
[4] Univ Hosp Careggi, Div Gastroenterol, I-50134 Florence, Italy
[5] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Gastroenterol Res Unit, Viale G B Morgagni 50, I-50134 Florence, Italy
关键词
Wilson's disease; Urinary copper excretion; Non-ceruloplasmin-bound copper; D-penicillamine; Trientine; Zinc salts; URINARY COPPER EXCRETION; ORAL ZINC THERAPY; D-PENICILLAMINE; HEPATOCELLULAR-CARCINOMA; CERULOPLASMIN; MANIFESTATIONS; DIAGNOSIS; TRIENTINE; METALLOTHIONEIN; ABSORPTION;
D O I
10.12998/wjcc.v10.i14.4334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Wilson's disease (WD) is a rare inherited disorder of human copper metabolism, with an estimated prevalence of 1:30000-1:50000 and a broad spectrum of hepatic and neuropsychiatric manifestations. In healthy individuals, the bile is the main route of elimination of copper. In WD patients, copper accumulates in the liver, it is released into the bloodstream, and is excreted in urine. Copper can also be accumulated in the brain, kidneys, heart, and osseous matter and causes damage due to direct toxicity or oxidative stress. Hepatic WD is commonly but not exclusively diagnosed in childhood or young adulthood. Adherent, non-cirrhotic WD patients seem to have a normal life expectancy. Nevertheless, chronic management of patients with Wilson's disease is challenging, as available biochemical tests have many limitations and do not allow a clear identification of non-compliance, overtreatment, or treatment goals. To provide optimal care, clinicians should have a complete understanding of these limitations and counterbalance them with a thorough clinical assessment. The aim of this review is to provide clinicians with practical tools and suggestions which may answer doubts that can arise during chronic management of patients with hepatic WD. In particular, it summarises current knowledge on Wilson's disease clinical and biochemical monitoring and treatment. It also analyses available evidence on pregnancy and the role of low-copper diet in WD. Future research should focus on trying to provide new copper metabolism tests which could help to guide treatment adjustments.
引用
收藏
页码:4334 / 4347
页数:15
相关论文
共 81 条
[1]   Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease [J].
Ala, Aftab ;
Aliu, Ermal ;
Schilsky, Michael L. .
DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (05) :1433-1439
[2]  
[Anonymous], 2004, Copper in drinking water. Background document for development of WHO Guidelines for Drinking-water Quality
[3]   Release behavior of metals from tin-lined copper cookware into food simulants during cooking and cold storage [J].
Banavi, Parvaneh ;
Sadeghi, Ehsan ;
Garavand, Farhad ;
Heydari, Mahshid ;
Rouhi, Milad .
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2020, 27 (31) :38591-38601
[4]   Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine [J].
Bécuwe, C ;
Dalle, S ;
Ronger-Savlé, S ;
Skowron, F ;
Balme, B ;
Kanitakis, J ;
Thomas, L .
DERMATOLOGY, 2005, 210 (01) :60-63
[5]   Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort [J].
Beinhardt, Sandra ;
Leiss, Waltraud ;
Staettermayer, Albert Friedrich ;
Graziadei, Ivo ;
Zoller, Heinz ;
Stauber, Rudolf ;
Maieron, Andreas ;
Datz, Christian ;
Steindl-Munda, Petra ;
Hofer, Harald ;
Vogel, Wolfgang ;
Trauner, Michael ;
Ferenci, Peter .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (04) :683-689
[6]  
Brewer G J, 2001, Expert Opin Pharmacother, V2, P1473, DOI 10.1517/14656566.2.9.1473
[7]   Treatment of Wilson disease with ammonium tetrathiomolybdate - IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease [J].
Brewer, GJ ;
Askari, F ;
Lorincz, MT ;
Carlson, M ;
Schilsky, M ;
Kluin, KJ ;
Hedera, P ;
Moretti, P ;
Fink, MK ;
Tankanow, R ;
Dick, RB ;
Sitterly, J .
ARCHIVES OF NEUROLOGY, 2006, 63 (04) :521-527
[8]   ORAL ZINC THERAPY FOR WILSONS-DISEASE [J].
BREWER, GJ ;
HILL, GM ;
PRASAD, AS ;
COSSACK, ZT ;
RABBANI, P .
ANNALS OF INTERNAL MEDICINE, 1983, 99 (03) :314-320
[9]   Treatment of Wilson's disease with zinc: XV - Long-term follow-up studies [J].
Brewer, GJ ;
Dick, RD ;
Johnson, VD ;
Brunberg, JA ;
Kluin, KJ ;
Fink, JK .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (04) :264-278
[10]   WORSENING OF NEUROLOGIC SYNDROME IN PATIENTS WITH WILSONS-DISEASE WITH INITIAL PENICILLAMINE THERAPY [J].
BREWER, GJ ;
TERRY, CA ;
AISEN, AM ;
HILL, GM .
ARCHIVES OF NEUROLOGY, 1987, 44 (05) :490-493